Differential expression of RAGE, EGFR and Ki-67 in primary tumors and lymph node deposits of breast carcinoma

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorAboushousha T.
dc.contributor.authorHammam O.
dc.contributor.authorSafwat G.
dc.contributor.authorEesa A.
dc.contributor.authorAhmed S.
dc.contributor.authorEsmat M.E.
dc.contributor.authorHelmy A.H.
dc.contributor.otherDepartment of Pathology
dc.contributor.otherCairo university
dc.contributor.otherCairo
dc.contributor.otherEgypt; Faculty of Biotechnology
dc.contributor.otherOctober University for Modern Sciences and Arts
dc.contributor.otherCairo university
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Pathology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherCairo university
dc.contributor.otherCairo
dc.contributor.otherEgypt; Department of Surgery
dc.contributor.otherTheodor Bilharz Research Institute
dc.contributor.otherCairo university
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:40:53Z
dc.date.available2020-01-09T20:40:53Z
dc.date.issued2018
dc.descriptionScopus
dc.descriptionMSA Google Scholar
dc.description.abstractBackground: Breast cancer is a complex disease that results from the inheritance of a number of susceptible genes. Intensive search wok was conducted world-wide on molecular bases of breast cancer in order to achieve the best therapeutic modalities; however, breast cancer still remains a challengeable task. It is very important to determine if the biological parameters in metastatic regional lymph nodes are similar to that in the primary breast cancer because therapy is indicated for patients with synchronous metastatic regional lymph nodes of breast cancer. Difference in therapeutic response in cases of breast cancer may be assumed partially to variability in the biological behavior of tumor tissue in primary breast cancer and lymph node metastasis. Aim: Our aim is to evaluate any variability in the expression of three types of tissue markers in both the primary breast tumors and corresponding axillary lymph nodes in order to expect the targeted therapeutic effect on both sites. Material and Methods: Three markers from different categories; RAGE, EGFR and Ki-67 were immunohistochemicalyl studied for their expression in biopsy specimens from primary breast tumors and their corresponding axillary lymph nodes. Results: There was a statistically significant difference in the expression of these markers between benign and malignant breast lesions.Although we found some differences in the expression of the three studied markers between primary breast cancer and corresponding axillary lymph nodes, yet these variations were mostly not statistically significant. Conclusion: Our findings support the validity of anti-RAGE and anti-EGFR therapy for treatment of both primary and nodal metastatic breast cancer in immunopositive cases. � 2018 Asian Pacific Organization for Cancer Prevention.en_US
dc.identifier.doihttps://doi.org/10.22034/APJCP.2018.19.8.2269
dc.identifier.doiPubMedID30139236
dc.identifier.issn15137368
dc.identifier.otherhttps://doi.org/10.22034/APJCP.2018.19.8.2269
dc.identifier.otherPubMedID30139236
dc.identifier.urihttps://t.ly/PGNbM
dc.language.isoEnglishen_US
dc.publisherWiley-VCH Verlag
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofseriesAsian Pacific Journal of Cancer Prevention
dc.relation.ispartofseries19
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectUniversity of Modern Sciences and Arts
dc.subjectMSA University
dc.subjectBreast canceren_US
dc.subjectEGFRen_US
dc.subjectIHCen_US
dc.subjectKi-67en_US
dc.subjectLymph node metastasisen_US
dc.subjectRAGEen_US
dc.subjectEGFR protein, humanen_US
dc.subjectepidermal growth factor receptoren_US
dc.subjectKi 67 antigenen_US
dc.subjectmitogen activated protein kinaseen_US
dc.subjectMOK protein, humanen_US
dc.subjecttumor antigenen_US
dc.subjecttumor markeren_US
dc.subjectadolescenten_US
dc.subjectadulten_US
dc.subjectbreast tumoren_US
dc.subjectcase control studyen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjecthumanen_US
dc.subjectlymph nodeen_US
dc.subjectlymph node metastasisen_US
dc.subjectmetabolismen_US
dc.subjectmiddle ageden_US
dc.subjectpathologyen_US
dc.subjectprognosisen_US
dc.subjectyoung adulten_US
dc.subjectAdolescenten_US
dc.subjectAdulten_US
dc.subjectAntigens, Neoplasmen_US
dc.subjectBiomarkers, Tumoren_US
dc.subjectBreast Neoplasmsen_US
dc.subjectCase-Control Studiesen_US
dc.subjectErbB Receptorsen_US
dc.subjectFemaleen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectHumansen_US
dc.subjectKi-67 Antigenen_US
dc.subjectLymph Nodesen_US
dc.subjectLymphatic Metastasisen_US
dc.subjectMiddle Ageden_US
dc.subjectMitogen-Activated Protein Kinasesen_US
dc.subjectPrognosisen_US
dc.subjectYoung Adulten_US
dc.titleDifferential expression of RAGE, EGFR and Ki-67 in primary tumors and lymph node deposits of breast carcinomaen_US
dc.typeArticleen_US
dcterms.isReferencedByArens, N., Bleyl, U., Hildenbrand, R., HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer (2005) Virchows Arch, 446, pp. 489-496; Buckley, A.F., Burgart, L.J., Sahai, V., Kakar, S., Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma (2008) Am J Clin Pathol, 129, pp. 245-251; Burcombe, R., Wilson, G.D., Dowsett, M., Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer (2006) Breast Cancer Res, 8; Burcombe, R.J., Makris, A., Richman, P.I., Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer (2005) Br J Cancer, 92, pp. 147-155; Buxant, F., Anaf, V., Simon, P., Fayt, I., Noel, J.C., Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor (2002) Breast Cancer Res Trea, 75, pp. 1-3; Cheng, H., Herndon, M.E., Lawler, J., Systemics RAGE is a biomarker of emphysemaand with AGER genetic variants in COPD patients (2013) Am J Respir Crit Care Med Metastasis, 19, pp. 1423-1437; Cho Eun, Y., Jae Joon, H., Yoon-La, C., Kyoung-Mee, K., Young, L.O., Comparison of Her-2, EGFR and Cyclin D1 in primary breast cancer and paired metastatic lymph nodes: An immunohistochemical and chromogenic in situ hybridization study (2008) J Korean Med Sci, 23, pp. 1053-1061; Cobleigh, M.A., Vogel, C.L., Tripathy, D., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease (1999) J Clin Oncol, 17, pp. 2639-2648; Dai, L., Liu, M., Zhu, Q., Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma (2014) Cancer Res, 74, p. 885; Inwald, E.C., Klinkhammer-Schalke, M., Hofst�dter, F., Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry (2013) Breast Cancer Res Treat, 139, pp. 539-552; Gown, A.M., Molecular vs. immunohistochemical classification of breast cancer (2009) Breast Cancer, pp. 28-30. , https://pdfs.semanticscholar.org/c2e8/6f2b50779ec877d705f1d9aa5b1d5de471f3.pdf; Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation and cancer (2010) Cell, 140, pp. 883-899; Hana, S., Sabine, M., Wang-Zaki, R., Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231 (2015) Biochim Biophys Acta, 1852, pp. 429-441; Harder, J., Waiz Otto, F., Geissler, M., EGFR and HER2 expression in advanced biliary tract cancer (2009) World J Gastroenterol, 15, pp. 4511-4517; Hecht, S.S., Tabacco smoke carcinogens and breast cancer (2002) Environ Mol Mutagen, 39, pp. 119-126; Hongming, P., Lan, H., Bin, W., Wenquan, N., The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese (2014) Sci Rep, 4, p. 4355; Howlader, N., Noone, A.M., Krapcho, M., (2015) SEER Cancer, , https://seer.cancer.gov/archive/csr/1975_2014/, Stat Rev, 1975-2012; Lata, K., Mukherjee, T.K., Knockdown of receptor for advanced glycation end productsattenuate17alpha-ethinyl-es tradioldependentproliferationand survival of MCF-7 breast cancer cells (2014) Biochim Biophys Acta, 1840, pp. 1083-1091; Lurje, G., Lenz, H.J., EGFR signaling and drug discovery (2009) Oncology, 77, pp. 400-410; Magkou, C., Lydia, N., Christina, Z., Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas (2008) Breast Cancer Res, 10; Martinazzi, M., Crivelli, F., Zampatti, C., Martinazzi, S., Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas An immunohistochemical study (1993) Pathologica, 85, pp. 637-644; Masuda, H., Dongwei, Z., Chandra, B., Role of epidermal growth factor receptor in breast cancer (2012) Breast Cancer Res Treat, 136; Mink, P.J., Shahar, E., Rosamond, W.D., Alberg, A.J., Serum insulin and glucose level and breast cancer incidence (2002) Am J Epidemiol, 4; Morinaga, S., Nakamura, Y., Sugano, N., Expression of epidermal growth factor receptor (EGFR) associates with proliferation, apoptosis and histologically aggressive features in hepatocellular carcinoma (2006) Ann. Meeting Proceedings, 24, p. 14039; Nasser, M.W., Wani, N.A., Ahirwar, D.K., RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment (2015) Cancer Res, 75, pp. 974-985; Neubauer, H., Gall, C., Vogel, U., Changes in tumour biological markers during primary systemic chemotherapy (PST) (2008) Anti Cancer Res, 28, pp. 1797-1804; Park, D., Karesen, R., Noren, T., Sauer, T., Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications (2007) Virchows Arch, 451, pp. 11-18; Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis (2013) Nat Med, 19, pp. 1423-1437; Radia, A.M., Yaser, A.M., Ma, X., Specific siRNA targeting receptor for advanced Glycation end products (RAGE) decreases proliferation in human breast cancer cell lines (2013) Int J Mol Sci, 14, pp. 7959-7978; Rojas, A., Figueroa, H., Morales, E., Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis (2010) Carcinogenesis, 31, pp. 334-341; Salomon, D.S., Brandt, R., Ciardiello, F., Normanno, N., Crit Epidermal growth factor-related peptides and their receptors in human malignancies (1995) Rev Oncol Hematol, 19, pp. 183-232; Schnitt, S.S., Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy (2010) Mod Pathol, 23, pp. 60-64; Slamon, D.J., Leyland-Jones, B., Shak, S., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 (2001) N Engl J Med, 344, pp. 783-792; Sobral-Leite, M., Lips, E.H., Vieira-Monteiro, H.A., Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients (2017) PLoS One, 12; Taguchi, A., Blood, D.C., Toro, G., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases (2000) Nature, 405, pp. 354-360; Tawfik, K., Kimler, B.F., Davis, M.K., Fan, F., Tawfik, O., Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant (2012) Hum Pathol, 44, pp. 39-46; Tesarov�, P., Kalousov�, M., J�chymov�, M., Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer (2007) Cancer Invest, 25, pp. 720-725; Thor, A., Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? (2001) J NatlCancer Inst, 93, pp. 1120-1121; Tokes, A.M., Szasz, A.M., Geszti, F., Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcino-mas and corresponding distant metastases (2015) J Clin Pathol, 68, pp. 274-282. , WWW.ijcep.com/ISSN:1936-2625/IJCEP0007867; Ye, Y., Qiu, T.H., Kavanaugh, C., Green, J.E., Molecular mechanism of breast cancer progression: Lessons from mouse mammary cancer models and gene expression profiling (2004) J Breast Cancer, 19, pp. 69-82; Zhanga, S., Xuwei, H., Sihua, Z., Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients (2013) Cell Physiol Biochem, 31, pp. 525-531; Zhao, S., Lanwei, X., Wenjun, L., Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer (2015) Int J Clin Exp Pathol, 8, pp. 5744-5748
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download
Thumbnail Image
Name:
APJCP-19-2269.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Faculty of Biotechnology Research Paper